|Dr. Thomas J. Schall Ph.D.||Founder, Pres, CEO & Chairman||968.76k||8.42M||1959|
|Ms. Susan M. Kanaya||Exec. VP, Chief Financial & Admin. Officer and Sec.||696.65k||10.18M||1963|
|Dr. Markus J. Cappel||Sr. VP, Chief Bus. Officer & Treasurer||563.8k||7.43M||1961|
|Ms. Kari E. Leetch||Sr. VP of HR||N/A||N/A||N/A|
|Dr. Catherine Lee Kelleher||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
|Ms. Dalia R. Rayes||Sr. VP & Head of Commercial||N/A||N/A||N/A|
|Dr. Sangita Ghosh Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
ChemoCentryx, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 9.